| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N R Biermasz, H V Dulken, F Roelfsem. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clinical endocrinology. vol 53. issue 3. 2000-10-10. PMID:10971449. |
postoperative radiotherapy in acromegaly is effective in reducing gh concentration to safe levels. |
2000-10-10 |
2023-08-12 |
Not clear |
| N R Biermasz, H V Dulken, F Roelfsem. Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels. Clinical endocrinology. vol 53. issue 3. 2000-10-10. PMID:10971449. |
several studies have established that in treated acromegaly mortality is only normalized in patients achieving a serum gh concentration below 5 mu/l. |
2000-10-10 |
2023-08-12 |
Not clear |
| V S Herman-Bonert, K Zib, J A Scarlett, S Melme. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. The Journal of clinical endocrinology and metabolism. vol 85. issue 8. 2000-08-31. PMID:10946911. |
transsphenoidal surgical resection is the primary therapy for acromegaly caused by gh secreting pituitary adenomas. |
2000-08-31 |
2023-08-12 |
Not clear |
| N R Biermasz, H van Dulken, F Roelfsem. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 85. issue 7. 2000-08-08. PMID:10902796. |
in acromegaly, pituitary irradiation is a slow, but effective, intervention in decreasing gh concentration. |
2000-08-08 |
2023-08-12 |
Not clear |
| N R Biermasz, H van Dulken, F Roelfsem. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 85. issue 7. 2000-08-08. PMID:10902796. |
we analyzed the long-term follow-up data of postoperatively administered radiotherapy in 36 patients with postoperative persistent acromegaly, using both the normalization of gh suppression during oral glucose loading (gtt) and the normalization of igf-i concentration as criteria for remission. |
2000-08-08 |
2023-08-12 |
Not clear |
| P M Stewart, R A Jame. The future of somatostatin analogue therapy. Bailliere's best practice & research. Clinical endocrinology & metabolism. vol 13. issue 3. 2000-08-03. PMID:10909432. |
in patients with acromegaly, depot preparations of these analogues are administered intramuscularly every 10-28 days and provide consistent suppression of gh levels to < 5 mu/l in approximately 50-65% of all cases. |
2000-08-03 |
2023-08-12 |
Not clear |
| C Parkinson, P J Traine. Growth hormone receptor antagonists therapy for acromegaly. Bailliere's best practice & research. Clinical endocrinology & metabolism. vol 13. issue 3. 2000-08-03. PMID:10909433. |
this chapter reviews the interaction between gh and the ghr, and discusses the outstanding issues regarding ghr antagonist therapy in acromegaly. |
2000-08-03 |
2023-08-12 |
Not clear |
| O M Herlihy, P Perro. Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma. Diabetes/metabolism research and reviews. vol 16. issue 3. 2000-08-02. PMID:10867721. |
the biochemical confirmation of acromegaly is rarely difficult and is based on an elevated fasting serum growth hormone (gh) concentration, which fails to suppress in response to an oral glucose load. |
2000-08-02 |
2023-08-12 |
Not clear |
| S Valdemarsson, S Ljunggren, M Bramnert, O Norrhamn, C H Nordströ. Early postoperative growth hormone levels: high predictive value for long-term outcome after surgery for acromegaly. Journal of internal medicine. vol 247. issue 6. 2000-07-25. PMID:10886485. |
to explore the prognostic value of early - within 1 week - postoperative growth hormone (gh) measurements with regard to outcome after surgery for acromegaly in a short- and a long-term perspective. |
2000-07-25 |
2023-08-12 |
Not clear |
| M Losa, W Saeger, P Mortini, C Pandolfi, M R Terreni, G Taccagni, M Giovanell. Acromegaly associated with a granular cell tumor of the neurohypophysis: a clinical and histological study. Case report. Journal of neurosurgery. vol 93. issue 1. 2000-07-19. PMID:10883914. |
acromegaly is usually caused by a growth hormone (gh)-secreting pituitary adenoma, and hypersecretion of gh-releasing hormone (ghrh) from a hypothalamic or neuroendocrine tumor accounts for other cases. |
2000-07-19 |
2023-08-12 |
Not clear |
| G Lombardi, C Di Somma, P Marzullo, G Cerbone, A Cola. Growth hormone and cardiac function. Annales d'endocrinologie. vol 61. issue 1. 2000-06-27. PMID:10790587. |
the abnormalities of cardiovascular system could be partially reverted by suppressing gh and igf-i levels in acromegaly or after gh remplacement therapy in ghd patients. |
2000-06-27 |
2023-08-12 |
Not clear |
| T Lei, X Bai, K Liu, W Hu, D Xue, X Jian. Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine. Journal of Tongji Medical University = Tong ji yi ke da xue xue bao. vol 18. issue 3. 2000-06-21. PMID:10806816. |
the inhibitory effect of bromocriptine (bc), a dopamine agonist, on growth hormone (gh) and prl secretion of dispersed cells from the pituitary adenomas of 16 cases of acromegaly, which secret gh and prl simultaneously, were evaluated in vitro. |
2000-06-21 |
2023-08-12 |
human |
| S B Raff, J A Carney, D Krugman, J L Doppman, C A Strataki. Prolactin secretion abnormalities in patients with the "syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). Journal of pediatric endocrinology & metabolism : JPEM. vol 13. issue 4. 2000-06-08. PMID:10776991. |
acromegaly due to growth hormone (gh)-producing adenomas has been considered the only pituitary-related manifestation of the complex. |
2000-06-08 |
2023-08-12 |
Not clear |
| S B Raff, J A Carney, D Krugman, J L Doppman, C A Strataki. Prolactin secretion abnormalities in patients with the "syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). Journal of pediatric endocrinology & metabolism : JPEM. vol 13. issue 4. 2000-06-08. PMID:10776991. |
in the present study, seven patients with carney complex, who belonged to three unrelated kindreds and had relatives with acromegaly, were investigated for the presence of gh and prolactin (prl) secretion abnormalities (familial cases). |
2000-06-08 |
2023-08-12 |
Not clear |
| F Manelli, S Bossoni, A Burattin, M Doga, S B Solerte, G Romanelli, A Giustin. Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog. Metabolism: clinical and experimental. vol 49. issue 5. 2000-06-08. PMID:10831175. |
moreover, the effect of acute but sustained gh inhibition in acromegaly on uae at rest and after exercise has never been studied. |
2000-06-08 |
2023-08-12 |
human |
| F Manelli, S Bossoni, A Burattin, M Doga, S B Solerte, G Romanelli, A Giustin. Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog. Metabolism: clinical and experimental. vol 49. issue 5. 2000-06-08. PMID:10831175. |
sr-l can significantly reduce uae at rest and after exercise in the short-term in acromegaly, probably via a decrease in circulating gh levels. |
2000-06-08 |
2023-08-12 |
human |
| N J Gittoes, M C Sheppard, A P Johnson, P M Stewar. Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. QJM : monthly journal of the Association of Physicians. vol 92. issue 12. 2000-05-12. PMID:10581337. |
previous large series of outcome following pituitary surgery for acromegaly, including our own, have demonstrated poor results, with cure, defined as gh <5 mu/l, achieved in only 33-42% of patients. |
2000-05-12 |
2023-08-12 |
Not clear |
| P Razzore, A Colao, R Baldelli, D Gaia, P Marzullo, E Ferretti, D Ferone, M L Jaffrain-Rea, G Tamburrano, G Lombardi, F Camanni, E Ciccarell. Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clinical endocrinology. vol 51. issue 2. 2000-05-09. PMID:10468985. |
we analysed the effects of 6-months' treatment with octreotide s.c. and lanreotide-sr on circulating gh and igf-i levels in acromegaly. |
2000-05-09 |
2023-08-12 |
Not clear |
| H E Turner, A Vadivale, J Keenan, J A Was. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical endocrinology. vol 51. issue 3. 2000-05-09. PMID:10469005. |
we wished to assess the effectiveness of both these drugs in suppressing mean gh to a target of < 5 mu/l in patients with acromegaly unselected for responsiveness to octreotide, and also to compare the effects of both drugs |
2000-05-09 |
2023-08-12 |
Not clear |
| P Marzullo, A Cuocolo, D Ferone, R Pivonello, M Salvatore, G Lombardi, A Cola. Cardiac effect of thyrotoxicosis in acromegaly. The Journal of clinical endocrinology and metabolism. vol 85. issue 4. 2000-05-01. PMID:10770177. |
four of these six patients (66%) had elevated gh and insulin-like growth factor i levels during the treatment of acromegaly. |
2000-05-01 |
2023-08-12 |
human |